Kisspeptin-10 10mg

Once-daily subcutaneous protocol for GnRH-stimulating reproductive peptide research.

Kisspeptin-10 10mg

Kisspeptin (also known as metastin) is a naturally occurring neuroendocrine peptide that plays a pivotal role in human reproduction by stimulating gonadotropin-releasing hormone (GnRH) secretion.

Vial Size
Dose Range
Schedule
Primary Goal
10mg vial) 100 to 200 mcg daily with gradual titration. Daily subcutaneous injections for 8 to 12 weeks. Support physiological reproductive hormone signaling through upstream GnRH stimulation.

Reconstitution Summary

1 mL per 10 mg vial (10 mg/mL).

Storage Summary

Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw.

Reconstitution Steps

  1. Draw 1 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl until dissolved (do not shake).
  4. Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

How It Works

Kisspeptin is an upstream trigger for the reproductive hormone cascade. Upon subcutaneous injection, kisspeptin rapidly binds to kisspeptin receptors (GPR54) on GnRH neurons in the hypothalamus, causing immediate release of GnRH. This in turn stimulates the anterior pituitary to secrete LH and FSH, which act on the gonads to boost sex steroid production and support gametogenesis. Importantly, kisspeptin’s action is GnRH-dependent: if GnRH release is blocked, kisspeptin cannot induce LH/FSH secretion. This confirms that kisspeptin works by unlocking the body’s own GnRH stores, providing a more physiologic pattern of hormone release compared to direct GnRH or hCG administration.

Benefits & Side Effects

  • Physiological sex hormone stimulation: increases endogenous testosterone and estrogen levels by
    amplifying the body’s own LH/FSH signals without suppressing the HPG axis.
  • Fertility restoration: shows promise in functional hypothalamic amenorrhea by rekindling GnRH/LH
    pulsatility and resuming menstrual cycles.
  • IVF ovulation trigger: can induce robust LH surge to mature oocytes while potentially lowering the risk of ovarian hyperstimulation syndrome compared to traditional hCG triggers.
  • Safety profile: generally well tolerated; occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.

References & Scientific Literature

  1. Emerging Therapeutic Potential of Kisspeptin and Neurokinin B (Endocrine Reviews).
  2. Kisspeptin-54 triggers egg maturation in IVF with reduced OHSS risk (J Clinical Investigation).
  3. Functional hypothalamic amenorrhea: restoration of GnRH pulsatility (Endocrine Reviews).
  4. Kisspeptin mechanism: GPR54 receptor binding and GnRH release (Endocrine Reviews).